Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARIA
  • CUSIP: 04033A10
  • Web:
Average Prices:
  • 50 Day Moving Avg: $21.86
  • 200 Day Moving Avg: $14.14
  • 52 Week Range: $4.67 - $23.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -57.12
  • P/E Growth: 0.00
  • Net Margins: -60.47%
  • Return on Assets: -17.16%
  • Debt-to-Equity Ratio: -11.28%
  • Current Ratio: 3.17%
  • Quick Ratio: 3.15%
  • Average Volume: 9.91 million shs.
  • Beta: 2.16

Frequently Asked Questions for Ariad Pharmaceuticals (NASDAQ:ARIA)

What is Ariad Pharmaceuticals' stock symbol?

Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."

How were Ariad Pharmaceuticals' earnings last quarter?

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released its earnings results on Thursday, July, 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.70. The firm had revenue of $65.30 million for the quarter, compared to analyst estimates of $60.64 million. Ariad Pharmaceuticals's revenue was up 133.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.28) earnings per share. View Ariad Pharmaceuticals' Earnings History.

Where is Ariad Pharmaceuticals' stock going? Where will Ariad Pharmaceuticals' stock price be in 2017?

9 brokers have issued 1 year price targets for Ariad Pharmaceuticals' stock. Their forecasts range from $7.00 to $24.00. On average, they expect Ariad Pharmaceuticals' share price to reach $16.11 in the next year. View Analyst Ratings for Ariad Pharmaceuticals.

Who are some of Ariad Pharmaceuticals' key competitors?

How do I buy Ariad Pharmaceuticals stock?

Shares of Ariad Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ariad Pharmaceuticals' stock price today?

One share of Ariad Pharmaceuticals stock can currently be purchased for approximately $23.99.

MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  411 (Vote Outperform)
Underperform Votes:  307 (Vote Underperform)
Total Votes:  718
MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $16.11 (32.85% downside)
Consensus Price Target History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Price Target History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/11/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$24.00N/AView Rating Details
1/10/2017Cowen and CompanyReiterated RatingBuy$16.00N/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
1/10/2017Barclays PLCUpgradeUnderweight -> Equal Weight$9.00 -> $24.00N/AView Rating Details
1/10/2017Jefferies Group LLCDowngradeBuy -> Hold$11.00 -> $24.00N/AView Rating Details
12/10/2016William BlairReiterated RatingOutperform$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageHold$9.50N/AView Rating Details
10/24/2016J P Morgan Chase & CoDowngradeNeutral -> Underweight$9.97 -> $7.00N/AView Rating Details
6/20/2016Royal Bank Of CanadaReiterated RatingHoldN/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$7.00 -> $5.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Earnings by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Earnings History by Quarter for Ariad Pharmaceuticals (NASDAQ ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q316($0.19)($0.14)$42.93 million$34.30 millionViewListenView Earnings Details
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.12)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314($0.30)($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.27)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
2017 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.21)($0.23)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.22)($0.22)($0.22)
Q4 20172($0.57)($0.21)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 86.97%
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Institutional Ownership by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Daniel M BollagVPSell32,000$23.78$760,960.00View SEC Filing  
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ariad Pharmaceuticals (NASDAQ:ARIA)
Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateHeadline logoBlueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations - October 10 at 5:24 PM logo​Shire officially inks sublease for former Ariad site in Cambridge - Boston Business Journal - October 5 at 6:50 PM logoTakeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal ... - Business Wire (press release) - September 28 at 8:00 AM logoIncyte seeking $666.6 million from stock sale - September 12 at 9:20 PM logoWhy Acadia Pharma Could be Worth $10 Billion | Investopedia - Investopedia - September 11 at 3:53 PM logoEton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - PR Newswire (press release) - September 9 at 3:50 PM logoEton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - PR Newswire (press release) - September 9 at 3:50 PM logoEton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - September 7 at 4:01 PM logoTakeda Pharmaceutical Prescribes Stability After Rough Start - September 5 at 10:42 PM logoTakeda CEO Prescribes Stability After Rough Start - September 5 at 5:39 PM logoJudge OKs ex-Ariad employee's SEC pact after questioning fairness - August 16 at 9:28 PM logoCompugen Welcomes Paul Sekhri as its New Chairman of the Board - PR Newswire (press release) - August 3 at 2:54 AM logoIncyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs - August 1 at 4:57 PM logoJapanese drugmaker Takeda posts stronger profit as US sales jump - Nasdaq - July 29 at 3:45 PM logoUPDATE 1-Japanese drugmaker Takeda posts stronger profit as US sales jump - Reuters - July 28 at 5:10 PM
News IconEx-Ariad employee's husband charged in US with insider trading - Business Insider - July 22 at 3:56 PM logoEx-Ariad employee's husband charged with insider trading - July 22 at 3:34 AM logoEx-Ariad employee's husband charged with insider trading - Reuters - Reuters - July 21 at 3:30 AM logoEx-Ariad employee's husband charged in U.S. with insider trading - Reuters - July 20 at 5:26 PM logoWhat Sprycel Could Mean for Bristol-Myers Squibb - July 10 at 4:02 PM logoMerrimack: A Special Situation With A Compelling Risk/Reward - July 6 at 5:23 PM logo​SEC charges two former Ariad Pharmaceuticals executives with ... - Boston Business Journal - June 29 at 5:06 PM logoSEC charges three with insider trading in cancer drug company - MarketWatch - June 27 at 3:45 PM logoMersana Therapeutics Kicks Off A Major IPO Week - June 26 at 9:14 PM logoBellevue Group AG Buys Align Technology Inc, Anthem Inc, Walgreens Boots Alliance Inc, Sells ... - May 12 at 4:10 PM logoAlnylam Pharma (ALNY) Names Manmeet S. Soni as CFO - - May 9 at 9:09 AM logoTakeda Announces Publication of ALUNBRIG™ (brigatinib) Pivotal Phase 2 ALTA Clinical Trial Data in Journal of Clinical Oncology - May 8 at 10:49 AM logoMonday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda - April 30 at 2:27 AM logoGeneral American Investors Co Inc Buys Ensco PLC, Johnson Controls International PLC, Liberty ... - April 29 at 4:14 PM logoEvercore Partners' (EVR) CEO Ralph Schlosstein on Q1 2017 Results - Earnings Call Transcript - April 26 at 3:53 PM logoAriad Pharmaceuticals (ARIA) Flat with Quarterly Loss Projected - April 12 at 11:48 AM logoTocagen IPO Could Garner Significant Investor Attention - April 11 at 8:05 AM logo7-Eleven to Buy Sunoco Shops in Record $3.3 Billion U.S. Bet - April 7 at 3:38 PM logoAfter Soaring to $150, Can Incyte Stir Up More Upside? - March 15 at 3:49 PM logoTrump???s Immigration Plans an Overhang on Biotech ETFs? - March 2 at 3:51 PM logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - Reuters - February 18 at 3:34 PM logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - February 17 at 6:32 PM logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US - February 16 at 8:41 PM logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US - February 16 at 8:41 PM logoTakeda Announces Completion of Acquisition of ARIAD Pharmaceuticals (ARIA) - February 16 at 8:41 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o - February 16 at 8:41 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o - February 16 at 8:41 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o - February 16 at 8:41 PM logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. - February 16 at 3:40 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - February 8 at 8:53 PM logoAriad Submits Brigatinib Marketing Application (ARIA) - February 7 at 1:44 AM logoARIAD Pharma Reports Submission Of MAA For Brigatinib To EMA - February 7 at 1:44 AM logo7:35 am Ariad Pharm submits a MMA for its ALK inhbiter, brigatinib, to the EMA - February 7 at 1:44 AM logoARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency - February 7 at 1:44 AM



Ariad Pharmaceuticals (ARIA) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.